Thus, multiple clinicopathological factors, such as the tumour size and lymph node metastasis, and established biomarkers, such as the estrogen receptor (ER), human epidermal growth factor receptor 2 (HER2), and progesterone receptor, have been used to characterise specific features of breast cancer, including its subtypes. This evidence concerns the gene ESR1 and neoplasm.